β-Amyloid Peptide (1-42), rat 2 mg | ≥95%
LKT Laboratories, Inc.
Endogenous APP peptide cleavage product, primary component in amyloid plaques typical of Alzheimer’s disease.
More Information Supplier PageSearch Results
β-Amyloid Peptide (1-42), rat 1 mg | ≥95%
LKT Laboratories, Inc.
Endogenous APP peptide cleavage product, primary component in amyloid plaques typical of Alzheimer’s disease.
More Information Supplier Pageβ-Amyloid Peptide (1-42), human 2.5 mg | ≥95%
LKT Laboratories, Inc.
Endogenous APP peptide cleavage product, primary component in amyloid plaques typical of Alzheimer’s disease.
More Information Supplier Pageβ-Amyloid Peptide (1-42), human 1 mg | ≥95%
LKT Laboratories, Inc.
Endogenous APP peptide cleavage product, primary component in amyloid plaques typical of Alzheimer’s disease.
More Information Supplier Pageα-ANP (1-28), human 1 mg | ≥95%
LKT Laboratories, Inc.
α-ANP (1-28), human 2.5 mg | ≥95%
LKT Laboratories, Inc.
[Des-Asp1]-Angiotensin I, human 25 mg | ≥95%
LKT Laboratories, Inc.
Peptide, derivative of AT I, cleavage product of angiotensin, precursor to AT II.
More Information Supplier Page[Des-Asp1]-Angiotensin I, human 10 mg | ≥95%
LKT Laboratories, Inc.
Peptide, derivative of AT I, cleavage product of angiotensin, precursor to AT II.
More Information Supplier Page[Des-Asp1]-Angiotensin I, human 5 mg | ≥95%
LKT Laboratories, Inc.
Peptide, derivative of AT I, cleavage product of angiotensin, precursor to AT II.
More Information Supplier Page